HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Parry, S.D. Articles by Barton, J.R. Search for Related Content PubMed PubMed Citation Articles by Parry, S.D. Articles by Barton, J.R.

Sulphasalazine and lung toxicity

Northumbria Division, University of Newcastle Faculty of Medicine, North Tyneside Hospital, North Shields, UK

CORRESPONDENCE: E.T. Peel, University of Newcastle Faculty of Medicine, North Tyneside General Hospital, Rake Lane, North Shields, NE29 8NH, UK. Fax: 44 1912932722. E-mail: Tim.Peel@northumbria-healthcare.nhs.uk

Keywords: adverse drug reaction, lung, pulmonary disease, sulphasalazine

Received: August 1, 2001
Accepted November 5, 2001

Abstract

Sulphasalazine prescribing is on the increase. Pulmonary toxicity and blood dyscrasias are rare side-effects. Numerous case reports have been published implicating sulphasalazine in pulmonary toxicity. The authors searched the literature for cases of sulphasalazine induced lung toxicity and the 50 cases identified are discussed here.

All published case reports/letters referring to sulphasalazine and lung toxicity were studied. The search terms "sulphasalazine" and "sulfasalazine" were combined with the terms "lung", "pulmonary disease", "pneumonitis" and "pleuritis" using Medline and PubMed databases.

Typical presentation of sulphasalazine-induced lung disease was with new onset dyspnoea and infiltrates on chest radiography. Common symptoms were cough and fever. Crepitations on auscultation and peripheral eosinophilia were noted in half of the cases. Sputum production, allergy history, rash, chest pain and weight loss were inconsistent findings. Pulmonary pathology was variable, the commonest being eosinophilic pneumonia with peripheral eosinophilia and interstitial inflammation with or without fibrosis. Fatal reports were infrequent. Most patients were managed by drug withdrawal with 40% prescribed corticosteroids.

In conclusion, sulphasalazine lung disease should be distinguished from interstitial lung disease due to underlying primary disease. Despite the increase in sulphasalazine prescribing, pulmonary toxicity remains rare. The majority of patients with suspected sulphasalazine-induced lung disease improved within weeks of drug withdrawal and the need for corticosteroids is debatable.

This article has been cited by other articles:

				C. M. Wiener, V. V. Muse, and E. J. Mark Case 33-2008 -- A 63-Year-Old Woman with Dyspnea on Exertion N. Engl. J. Med., October 23, 2008; 359(17): 1823 - 1832. [Full Text] [PDF]

				H. Black, M. Mendoza, and S. Murin Thoracic Manifestations of Inflammatory Bowel Disease Chest, February 1, 2007; 131(2): 524 - 532. [Abstract] [Full Text] [PDF]